FindTrial
Sign In

Changes in Hand Bone Mass and Bone Metabolism in Rheumatoid Arthritis Patients after Treatment with Methotrexate or Iguratimod: A Retrospective Study

Changes in Hand Bone Mass and Bone Metabolism in Rheumatoid Arthritis Patients after Treatment with Methotrexate or Iguratimod: A Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125224
Enrollment
Unknown
Registered
2026-05-22
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Iguratimod group:None
methotrexate group:None

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meeting the 1987 American College of Rheumatology (ACR) classification criteria for RA or the 2010 ACR/EULAR revised classification criteria for RA; 2.Receiving monotherapy with methotrexate or iguratimod, without the use of calcium or vitamin D preparations; 3.Being followed up after 6 months and/or 18 months of treatment with complete data available.

Exclusion criteria

Exclusion criteria: 1.Incomplete examination data. 2.Patients with severe liver or kidney dysfunction, Cushing's syndrome, thyroid and parathyroid disorders, malignant tumors, or other conditions affecting bone metabolism.

Design outcomes

Primary

MeasureTime frame
Changes in bone metabolism levels;—

Secondary

MeasureTime frame
Hand bone density levels;—

Countries

China

Contacts

Public ContactTianle Wang

Zhejiang Provincial People's Hospital

873804802@qq.com+86 571 8589 3940

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026